Compare Nike Inc (NKE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nike Inc trades at $40.59 (market cap $61.30B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Nike Inc pays a 3.97% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nike Inc nearer its low. Which is the better fit depends on your goals.
| NKE | XBI | |
|---|---|---|
Market Cap | $61.30B | — |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $79.17 | $164.28 |
52-Week Low | $40.75 | $86.92 |
Enterprise Value | $63.30B | — |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $42.11, up 0.98% on the day, showing resilience amid a challenging period. The stock faces bearish technical signals but maintains strong profitability metrics including 42.91% gross margin and 22.14% ROE. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.72 significantly exceeding the $0.11 forecast. However, revenue declined to $46.31B in 2025 from $51.4B in 2024, reflecting ongoing business headwinds.
Nike's investment case balances strong brand value and consistent earnings beats against revenue pressures and competitive challenges. The consensus price target of $50.45 suggests 20% upside potential, though technical indicators remain bearish. Key risks include China market weakness and inventory management issues, while opportunities lie in digital transformation and product innovation driving future growth.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
